Stocks · Healthcare · Biotechnology
IDEAYA Biosciences, Inc. IDYA
$37.36 -1.19% Close, Oct 2, 2026 · NASDAQ · Market cap $3.55B
Strong growth
Next earnings report: Nov 9, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $234.1M, up 3244.7% from a year earlier, accelerating from 3118.1% a quarter earlier.
- Operating margin widened to -92.7% from -5488.9% a year earlier.
- The stock is in an uptrend: above its 200-day average for 75 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 2%
- Revenue growth, 3-year CAGRTop 10%
- Revenue growth accelerationTop 3%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 48%
- Gross marginBottom 7%
- Operating marginBottom 30%
- Accruals (lower is better)Bottom 42%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 44%
- Free-cash-flow yieldTop 47%
- EBITDA / enterprise valueBottom 47%
- Sales / enterprise valueBottom 25%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 35%
- 6-month returnTop 44%
- 1-year return vs S&P 500Top 32%
- Distance from 52-week highTop 20%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 11%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 23%
- Upside to consensus price targetBottom 44%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 13%
- Maximum drawdown, 3 yearsTop 49%
- Beta vs S&P 500 (lower is better)Bottom 40%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 3118.1% | 3244.7% | ↑ |
| Gross margin | -1996.7% | -13.3% | ↑ |
| Operating margin | -5488.9% | -92.7% | ↑ |
| FCF margin | -4246.5% | -48.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 3244.7% | 3118.1% | ↑ | Top 2% |
| Gross margin | -13.3% | -1996.7% | ↑ | Bottom 7% |
| Operating margin | -92.7% | -5488.9% | ↑ | Bottom 30% |
| Net margin | -74.8% | -4740.0% | ↑ | — |
| Free-cash-flow margin | -48.6% | -4246.5% | ↑ | — |
| Return on invested capital | -17.7% | — | Top 48% | |
| Revenue growth, 3-year CAGR | 62.5% | — | Top 10% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.8%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 23.6%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -4.12%
- Shareholder yield
- -4.12%
- Share count change, 1 year
- +4.1%
- Share count change, 3-year CAGR
- +17.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +55.7%
- Average 2-day reaction, last 8
- -2.1%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $57.00
- Target vs current price
- +52.6%
- Analysts with a rating
- 26
- Share rating Buy or Strong Buy
- 92%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | -15.1% | +2.0% | +3.8% | +13.3% | — |
| May 5, 2026 | -3.7% | -0.3% | -2.7% | -3.6% | +26.0% |
| Feb 17, 2026 | +1.2% | +1.6% | +6.1% | +14.9% | -7.1% |
| Nov 4, 2025 | +240.6% | -2.8% | -1.5% | +7.4% | +2.6% |
| Aug 5, 2025 | -3.5% | -3.5% | -8.6% | +1.9% | +32.8% |
| May 6, 2025 | -9.3% | -13.3% | -10.4% | +5.7% | +19.0% |
| Feb 13, 2025 | -122.4% | -5.4% | -1.0% | -13.6% | -20.6% |
| Nov 4, 2024 | +10.4% | +4.9% | +9.4% | -4.0% | -14.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$1.22 | -$1.06 | -15.1% | $8.9M |
| May 5, 2026 | -$1.11 | -$1.07 | -3.7% | $6.6M |
| Feb 17, 2026 | -$0.94 | -$0.95 | +1.2% | $10.9M |
| Nov 4, 2025 | $1.33 | -$0.95 | +240.6% | $207.8M |
| Aug 5, 2025 | -$0.88 | -$0.85 | -3.5% | — |
| May 6, 2025 | -$0.82 | -$0.75 | -9.3% | — |
| Feb 13, 2025 | -$1.49 | -$0.67 | -122.4% | $7.0M |
| Nov 4, 2024 | -$0.60 | -$0.67 | +10.4% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 14.13× | — | — | Bottom 25% |
| Free-cash-flow yield | -3.21% | — | — | Top 47% |
| Earnings yield | -5.19% | — | — | Top 44% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 75
- 50-day average slope (20 days)
- +1.3%
- 200-day average slope (20 days)
- +1.1%
- Distance from 50-day average
- -1.7%
- Distance from 200-day average
- +9.6%
- RSI (14)
- 45.4
- Relative volume
- 0.67×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 33.0%
- Volatility vs own 5-year history
- 0th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.29
- Correlation with S&P 500
- 0.42
- Current drawdown from 1-year high
- -12.1%
- Maximum drawdown, 3 years
- -69.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 22, 2021 | May 9, 2022 | -69.4% | 158 days | 323 days (Aug 22, 2023) |
| Feb 16, 2024 | Apr 8, 2025 | -69.2% | 285 days | Not yet recovered |
| Apr 5, 2021 | Jul 8, 2021 | -30.5% | 66 days | 40 days (Sep 2, 2021) |
| Dec 8, 2020 | Dec 29, 2020 | -27.7% | 14 days | 13 days (Jan 19, 2021) |
| Sep 1, 2023 | Oct 16, 2023 | -17.4% | 30 days | 17 days (Nov 8, 2023) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $3.55B
- EPS, diluted (TTM)
- -$1.94
- Revenue (TTM)
- $234.1M
- 52-week range
- $26.05 – $42.68
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M |
| Gross profit | $26.2M | $48.8M | $19.4M | $3.2M | -$96.0M |
| Operating income | -$50.3M | -$62.5M | -$134.4M | -$327.0M | -$159.3M |
| Net income | -$49.8M | -$58.7M | -$113.0M | -$274.5M | -$113.7M |
| EPS (diluted) | -$1.41 | -$1.42 | -$1.96 | -$3.36 | -$1.28 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $7.0M | $0 | $0 | $207.8M | $10.9M | $6.6M | $8.9M |
| Net income | -$51.8M | -$130.3M | -$72.2M | -$77.5M | $119.2M | -$83.3M | -$98.5M | -$112.5M |
| EPS (diluted) | -$0.60 | -$1.49 | -$0.82 | -$0.88 | $1.33 | -$0.94 | -$1.11 | -$1.22 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$55.8M | -$87.2M | -$115.2M | -$247.6M | -$71.1M |
| Capital expenditure | -$2.6M | -$3.4M | -$2.4M | -$3.9M | -$2.4M |
| Free cash flow | -$58.4M | -$90.6M | -$117.6M | -$251.4M | -$73.5M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $143.3M | $95.0M | $309.8M | $654.2M | $29.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $829.0M
- Total assets
- $1.31B
- Total liabilities
- $110.8M
- Total debt
- $29.3M
- Net debt
- -$243.3M
- Shareholders’ equity
- $1.20B
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 9,931,622
- Days to cover
- 17.26
- Change vs previous report
- -1.7%
FINRA short interest, settlement date Sep 15, 2026.